Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study
- PMID: 24470106
- DOI: 10.1002/art.38368
Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study
Abstract
Objective: High-dose methotrexate (MTX) exposure during pregnancy is associated with embryopathy. The teratogenic potential of MTX at dosages typically used in the treatment of rheumatic diseases remains uncertain. The aim of this study was to evaluate the risk of spontaneous abortion, major birth defects, elective termination of pregnancy, shortened gestational age at delivery, and reduced birth weight in women exposed to MTX.
Methods: Pregnancy outcome in women taking MTX (≤30 mg/week) either after conception or within the 12 weeks before conception was evaluated in a prospective observational multicenter cohort study. Pregnancy outcomes in the MTX group were compared to outcomes in a group of disease-matched women and a group of women without autoimmune diseases (neither group was exposed to MTX).
Results: The study sample included 324 MTX-exposed pregnancies (188 exposed post-conception, 136 exposed pre-conception), 459 disease-matched comparison women, and 1,107 comparison women without autoimmune diseases. In the post-conception cohort, the cumulative incidence of spontaneous abortion was 42.5% (95% confidence interval [95% CI] 29.2-58.7), which was significantly higher than the incidence of spontaneous abortion in either comparison group. The risk of major birth defects (7 of 106 [6.6%]) was elevated compared to both the cohort of women without autoimmune diseases (29 of 1,001 [2.9%]) (adjusted odds ratio [OR] 3.1 [95% CI 1.03-9.5]) and the disease-matched cohort (14 of 393 [3.6%]) (adjusted OR 1.8 [95% CI 0.6-5.7]). None of the malformations were clearly consistent with MTX embryopathy. Neither the cumulative incidence of spontaneous abortion (14.4% [95% CI 8.0-25.3]) nor the risk of major birth defects (4 of 114 [3.5%]) was increased in the pre-conception cohort. Elective termination rates were increased in both of the MTX-exposed cohorts. There were no other significant differences among groups in other study end points.
Conclusion: Post-conception administration of MTX at dosages typically used in the treatment of rheumatic diseases was associated with an increased risk of major birth defects and spontaneous abortion. Such evidence was not found among women in our pre-conception cohort.
Copyright © 2014 by the American College of Rheumatology.
Similar articles
-
[Pregnancy outcome after preconceptional exposure to methotrexate for ectopic pregnancy].Therapie. 2016 Sep;71(4):389-94. doi: 10.1016/j.therap.2015.12.005. Epub 2016 Feb 15. Therapie. 2016. PMID: 27203166 French.
-
Methotrexate embryopathy after exposure to low weekly doses in early pregnancy.Reprod Toxicol. 2014 Jan;43:26-9. doi: 10.1016/j.reprotox.2013.10.005. Reprod Toxicol. 2014. PMID: 24513926
-
No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study.Rheumatology (Oxford). 2014 Apr;53(4):757-63. doi: 10.1093/rheumatology/ket390. Epub 2013 Dec 24. Rheumatology (Oxford). 2014. PMID: 24369411
-
Use of methotrexate in young patients with respect to the reproductive system.Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S80-4. Epub 2010 Oct 28. Clin Exp Rheumatol. 2010. PMID: 21044438 Review.
-
Low dose weekly methotrexate in early pregnancy. A case series and review of the literature.J Rheumatol. 2000 Aug;27(8):1872-5. J Rheumatol. 2000. PMID: 10955326 Review.
Cited by
-
Safety surveillance for PrEP in pregnant and breastfeeding women.Front Reprod Health. 2023 Sep 29;5:1221101. doi: 10.3389/frph.2023.1221101. eCollection 2023. Front Reprod Health. 2023. PMID: 37854936 Free PMC article. Review.
-
IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.J Clin Med. 2023 Sep 25;12(19):6192. doi: 10.3390/jcm12196192. J Clin Med. 2023. PMID: 37834837 Free PMC article. Review.
-
2022 Chinese guideline for the management of pregnancy and reproduction in systemic lupus erythematosus.Rheumatol Immunol Res. 2023 Sep 27;4(3):115-138. doi: 10.2478/rir-2023-0019. eCollection 2023 Sep. Rheumatol Immunol Res. 2023. PMID: 37781682 Free PMC article. Review.
-
Inflammatory bowel disease in pregnancy and breastfeeding.Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):504-523. doi: 10.1038/s41575-023-00758-3. Epub 2023 Mar 31. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37002407 Review.
-
Methotrexate in pregnancy: still many unanswered questions.RMD Open. 2023 Mar;9(1):e002899. doi: 10.1136/rmdopen-2022-002899. RMD Open. 2023. PMID: 36921981 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical